About 22 million Americans would face sharply higher healthcare costs if enhanced ACA tax credits expire at the end of the ...

The accelerated FDA approval of Bayer's Hyrnuo covers treatment of advanced cases of non-small cell lung cancer with HER2 ...

Function Health raised a $298 million Series B round, pushing its valuation into unicorn territory at $2.5 billion. The ...

Much like the original fall of Babylon two and a half millennia ago, the collapse of Babylon Health was an inevitable end to an untenable empire. It grew too fast, without enough regard for patient ...

Direct primary care company Vitable has raised $16 million in Series A funding, which it will use to expand into new markets, the startup announced Friday. Philadelphia-based Vitable works with small ...

A recent survey conducted by the Service Employees International Union finds 89% of polled nurses and healthcare workers at HCA Healthcare felt being short-staffed at their hospital is “compromising ...

There are numerous challenges that insurers face when it comes to deploying artificial intelligence. However, according to one payer exec, insurers need to face these challenges head-on. “The worst ...

From L-R: Betty Pio, partner at Kearney; Dr. Rekha Kumar, chief medical officer at Found and practicing endocrinologist at New York-Presbyterian; Sheila Shah, managing director, L.E.K. Consulting; ...

The 340B Drug Pricing Program was designed to help safety net providers serve low-income patients, but it has since ballooned into a multibillion-dollar system dominated by large health systems — with ...

In the Byzantine world of health care pricing, most people wouldn’t expect that the ubiquitous flu shot could be a prime example of how the system’s lack of transparency can lead to disparate costs.

Oral Genome, a leader in saliva-based oral health testing, has been honored with the 2025 Cellerant Best of Class Hygiene Award, recognizing the company’s innovative contribution to preventive oral ...

A Merck drug developed to prevent disease from respiratory syncytial virus (RSV) in infants has won FDA approval, introducing competition to products already available from Pfizer and Sanofi. The ...